PRAXIS PRECISION MEDICINES PRAX 深 沪
已收盘 10-10 16:00:00 美东时间
53.26
-1.500
-2.74%
华盛通- 最 高55.105
- 今 开54.86
- 成交量 24.54万股
- 最 低 51.99
- 昨 收 54.76
- 总市值 11.21亿
- 52周最高 91.83
- 市盈率 静 --
- 换手率 1.17%
- 52周最低 26.70
- 委 比 5.91%
- 总股本 2104.96万
- 历史最高 914.265
- 量 比 0.63
- 振 幅 5.69%
- 历史最低 11.85
- 每 手 1
- 风险率 16.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Jones Trading Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $83
Jones Trading analyst Justin Walsh initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $83.
09-18 18:53
Praxis Home Retail Limited Announces 14th Annual General Meeting
An update from Praxis Home Retail Ltd. ( ($IN:PRAXIS) ) is now available. Praxi...
09-07 00:35
Praxis Precision Medicines Signs New Sales Agreement
Praxis Precision Medicines ( ($PRAX) ) has shared an update. Praxis Precision M...
09-06 05:20
Praxis Precision Medicines To Present 12 Epilepsy Pipeline Updates, Including RADIANT Results, At IEC 2025 In Lisbon
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced its participation in the upcoming
08-26 04:02
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
Praxis Precision Medicines将参加2025年8月30日至9月3日在葡萄牙里斯本举行的国际 epilepsy congress (IEC)，并将在会上展示其精准癫痫药物 pipeline 的最新进展。公司将在12个演讲中分享三项药物的临床和 preclinical data： 1. Vormatrigine：展示了RADIANT研究在 focal onset seizures 中的阳性结果，以及 phase 1 首次人体研究的更新，支持其在 epilepsy 领域的突破性进展。 2. Relutrigine：分享了EMBOLD研究在SCN2A和SCN8A-DEE方面的最新数据，强调其在广泛DEE中解决未满足需求的潜力。 3. Elsunersen：展示了EMRAVE3 注册研究的进展，及其在早期SCN2A增益功能DEE中的潜在长期益处。 此外，Praxis还将在展亭435展示更多癫痫研究，突出其以患者为中心的治疗开发方法。公司已安排多场科学演讲，包括平台演讲和海...
08-25 20:01
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures.
08-05 01:38
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines, a clinical-stage biopharmaceutical company focusing on developing therapies for CNS disorders, announced that its CEO Marcio Souza will participate in a virtual fireside chat hosted by analyst Joon Lee from Truist Securities on August 5, 2025 at 10:00am EST. Registration details are available via the provided link. The company translates genetic insights into innovative treatments for neuronal excitation-inhibition imb...
08-05 00:24
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Praxis Precision Medicines reported positive results from the RADIANT study for vormatrigine in focal onset seizures, showing a 56.3% reduction in seizure frequency and 22% of patients achieving 100% seizure reduction. The company also initiated registrational studies for its developmental epilepsy programs, including EMERALD for relutrigine and EMBRAVE3 for elsunersen. Relutrigine received FDA Breakthrough Therapy Designation for seizures associ...
08-04 12:30
